WO2004011625A2 - Polymorphisms for predicting disease and treatment outcome - Google Patents

Polymorphisms for predicting disease and treatment outcome Download PDF

Info

Publication number
WO2004011625A2
WO2004011625A2 PCT/US2003/024065 US0324065W WO2004011625A2 WO 2004011625 A2 WO2004011625 A2 WO 2004011625A2 US 0324065 W US0324065 W US 0324065W WO 2004011625 A2 WO2004011625 A2 WO 2004011625A2
Authority
WO
WIPO (PCT)
Prior art keywords
gene
cancer
patients
polymoφhism
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/024065
Other languages
English (en)
French (fr)
Other versions
WO2004011625A3 (en
Inventor
Heinz-Josef Lenz
Jan Stoehlmacher
David Park, (Jong-Han)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Priority to CA002494262A priority Critical patent/CA2494262A1/en
Priority to JP2004524265A priority patent/JP2005534686A/ja
Priority to US10/522,664 priority patent/US7662553B2/en
Priority to AU2003257110A priority patent/AU2003257110A1/en
Priority to EP03772163A priority patent/EP1540012A4/en
Publication of WO2004011625A2 publication Critical patent/WO2004011625A2/en
Publication of WO2004011625A3 publication Critical patent/WO2004011625A3/en
Anticipated expiration legal-status Critical
Priority to US12/650,323 priority patent/US20100173922A1/en
Priority to US13/275,225 priority patent/US20120122946A1/en
Priority to US13/757,610 priority patent/US20130196955A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Definitions

  • the PCR procedure describes a method of gene amplification which is comprised of (i) sequence-specific hybridization of primers to specific genes within a DNA sample (or library), (ii) subsequent amplification involving multiple rounds of annealing, elongation, and denaturation using a DNA polymerase, and (iii) screening the PCR products for a band of the correct size.
  • the primers used are oligonucleotides of sufficient length and appropriate sequence to provide initiation of polymerization, i.e. each primer is specifically designed to be complementary to each strand of the genomic locus to be amplified. Reagents and hardware for conducting PCR are commercially available.
  • synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions.
  • Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.
  • the suitable tissue or cell sample comprises normal tissue adjacent to the site of tumor biopsy or resection.
  • tissue adjacent mean about .5 mm, or about 1.0 mm, or about 1.5 mm, or about 2.0 mm or about 2.5 mm, or about 3.0 mm, or about 3.5 mm, or about 4.0 mm or about 4.5 mm or about 5.0 mm or alternatively any distance the only limitation being that the normal tissue be of the same type as the tumor or neoplasm.
  • This GSTPI polymo ⁇ hism can be become a useful marker to identify patients with an increased risk to fail this third-line chemotherapy, thus sparing those heavily pretreated patients the side effects of a 5-FU/oxaliplatin therapy and refer them to other therapy alternatives.
  • the procedure of a simple blood test may be enable the clinician to design more individualized chemotherapy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2003/024065 2002-07-31 2003-07-31 Polymorphisms for predicting disease and treatment outcome Ceased WO2004011625A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002494262A CA2494262A1 (en) 2002-07-31 2003-07-31 Polymorphisms for predicting disease and treatment outcome
JP2004524265A JP2005534686A (ja) 2002-07-31 2003-07-31 疾患および処置結果の予見のための多型性
US10/522,664 US7662553B2 (en) 2002-07-31 2003-07-31 Polymorphisms in the ERCC1 gene for predicting treatment outcome
AU2003257110A AU2003257110A1 (en) 2002-07-31 2003-07-31 Polymorphisms for predicting disease and treatment outcome
EP03772163A EP1540012A4 (en) 2002-07-31 2003-07-31 POLYMORPHISMS FOR PREDICTING A DISEASE AND TREATMENT RESULT
US12/650,323 US20100173922A1 (en) 2002-07-31 2009-12-30 Polymorphisms for Predicting Disease and Treatment Outcome
US13/275,225 US20120122946A1 (en) 2002-07-31 2011-10-17 Polymorphisms for predicting disease and treatment outcome
US13/757,610 US20130196955A1 (en) 2002-07-31 2013-02-01 Polymorphisms for predicting disease and treatment outcome

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US40025002P 2002-07-31 2002-07-31
US40024902P 2002-07-31 2002-07-31
US40025302P 2002-07-31 2002-07-31
US40027602P 2002-07-31 2002-07-31
US60/400,250 2002-07-31
US60/400,249 2002-07-31
US60/400,276 2002-07-31
US60/400,253 2002-07-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/650,323 Continuation US20100173922A1 (en) 2002-07-31 2009-12-30 Polymorphisms for Predicting Disease and Treatment Outcome

Publications (2)

Publication Number Publication Date
WO2004011625A2 true WO2004011625A2 (en) 2004-02-05
WO2004011625A3 WO2004011625A3 (en) 2004-11-11

Family

ID=31192379

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/024065 Ceased WO2004011625A2 (en) 2002-07-31 2003-07-31 Polymorphisms for predicting disease and treatment outcome

Country Status (6)

Country Link
US (4) US7662553B2 (enExample)
EP (4) EP2385137A1 (enExample)
JP (1) JP2005534686A (enExample)
AU (1) AU2003257110A1 (enExample)
CA (1) CA2494262A1 (enExample)
WO (1) WO2004011625A2 (enExample)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005098034A1 (en) * 2004-04-08 2005-10-20 Hiltrud Brauch Ercc2 polymorphisms
WO2005085473A3 (en) * 2004-03-01 2006-03-02 Univ Chicago Polymorphisms in the epidermal growth factor receptor gene promoter
WO2006106316A2 (en) 2005-04-04 2006-10-12 Dxs Limited Polynucleotide primers
US7138388B2 (en) 2001-01-19 2006-11-21 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions
WO2008088855A3 (en) * 2007-01-18 2008-12-11 Univ Southern California Gene polymorphisms as predictors of tumor progression and their use in cancer therapy
WO2008021483A3 (en) * 2006-08-17 2009-03-26 Ordway Res Inst Prognostic and diagnostic method for disease therapy
WO2007103823A3 (en) * 2006-03-03 2009-04-09 Univ Southern California Genetic markers for predicting disease and treatment outcome
WO2008089465A3 (en) * 2007-01-18 2009-04-23 Univ Southern California Gene polymorphisms as sex-specific predictors in cancer therapy
EP1991268A4 (en) * 2006-03-03 2009-08-26 Univ Southern California ANGIOGENIC PATH GENEPOLYMORPHISMS FOR THERAPY SELECTION
WO2009113989A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
EP1654526A4 (en) * 2003-07-18 2009-12-02 Intelligenescan Inc SPECIAL GROUP OF BIOLOGICAL MARKERS FOR COLORECTAL CANCER
US7662553B2 (en) 2002-07-31 2010-02-16 University Of Southern California Polymorphisms in the ERCC1 gene for predicting treatment outcome
WO2010124239A3 (en) * 2009-04-24 2011-01-06 University Of Southern California Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancer
US7890267B2 (en) 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
US8278061B2 (en) 2007-01-18 2012-10-02 University Of Southern California Polymorphisms in the EGFR pathway as markers for cancer treatment
US8435752B2 (en) 2007-01-18 2013-05-07 University Of Southern California Gene polymorphisms predictive for dual TKI therapy
US8568968B2 (en) 2009-04-13 2013-10-29 University Of Southern California EGFR polymorphisms predict gender-related treatment
US10342765B2 (en) 2009-02-06 2019-07-09 University Of Southern California Therapeutic compositions comprising monoterpenes

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2390051A1 (en) * 1999-11-15 2001-05-25 University Of Southern California Thymidylate synthase polymorphism for predicting chemotherapeutic response
EP1774039A4 (en) * 2004-07-01 2009-07-08 Univ Southern California GENETIC MARKERS FOR PREDICTING THE DISEASE AND TREATMENT OUTPUT
WO2007064957A1 (en) * 2005-11-30 2007-06-07 University Of Southern California FCγ POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME
EP1991707A4 (en) 2006-03-03 2012-11-21 Univ Southern California POLYMORPHISMS IN VOLTAGE-CONTROLLED SODIUM CHANNEL ALPHA-1 SUB-UNIT AS A MARKER FOR THERAPY SELECTION
FR2906532B1 (fr) * 2006-09-28 2008-12-12 Biomerieux Sa Nouvel oligonucleotide marque
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US20100184773A1 (en) * 2007-05-18 2010-07-22 Heinz-Josef Lenz Germline Polymorphisms in the Angiogenic Pathway Predict Tumor Recurrence in Cancer Therapy
EP2175722A4 (en) * 2007-07-12 2010-08-25 Tragara Pharmaceuticals Inc PATIENT SELECTION AND THERAPEUTIC PROCEDURES WITH PROSTAGLAND INMETABOLISM MARKERS
BRPI0814542A2 (pt) 2007-07-12 2014-09-30 Tragara Pharmaceuticals Inc Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
DE102007036404A1 (de) * 2007-07-27 2009-01-29 Eberhard-Karls-Universität Tübingen Universitätsklinikum Nachweis der Platinresistenz
EP2283148A4 (en) * 2008-04-25 2011-11-30 Integrated Bioscience Solutions Llc CYTOLOGICAL METHODS FOR CANCER SCREENING
EP2285976A4 (en) * 2008-05-15 2011-10-26 Univ Southern California ERCC-1 EXPRESSION AS A PROGNOSIS FOR CHEMOTHERAPEUTIC RESULTS
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
EP3360978A3 (en) 2009-05-07 2018-09-26 Veracyte, Inc. Methods for diagnosis of thyroid conditions
EP2311977A1 (en) * 2009-10-15 2011-04-20 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting responsiveness of a patient to a chemoradiation treatment
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
WO2013090620A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US11035005B2 (en) 2012-08-16 2021-06-15 Decipher Biosciences, Inc. Cancer diagnostics using biomarkers
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
CN114606309A (zh) 2014-11-05 2022-06-10 威拉赛特公司 使用机器学习和高维转录数据的诊断系统和方法
CN110506127B (zh) 2016-08-24 2024-01-12 维拉科特Sd公司 基因组标签预测前列腺癌患者对术后放射疗法应答性的用途
US11208697B2 (en) 2017-01-20 2021-12-28 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
US12497660B2 (en) 2017-08-04 2025-12-16 Veracyte SD, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
RU2732336C1 (ru) * 2020-01-14 2020-09-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ прогнозирования эффективности неоадъювантной химиолучевой терапии при аденокарциноме прямой кишки

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
EP0500727B1 (en) 1989-11-13 1998-01-21 Children's Medical Center Corporation Non-invasive method for isolation and detection of fetal dna
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
EP0636186B1 (en) 1992-04-03 1998-11-25 The Perkin-Elmer Corporation Probe composition and method
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
WO1994021822A1 (en) 1993-03-19 1994-09-29 Sequenom, Inc. Dna sequencing by mass spectrometry via exonuclease degradation
US5593826A (en) 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5705336A (en) * 1995-03-07 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Assay for sensitivity of tumors to DNA-platinating chemotherapy
US5571676A (en) 1995-06-07 1996-11-05 Ig Laboratories, Inc. Method for mismatch-directed in vitro DNA sequencing
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
US5985561A (en) * 1996-06-03 1999-11-16 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery FC receptor polymorphism
CA2390051A1 (en) * 1999-11-15 2001-05-25 University Of Southern California Thymidylate synthase polymorphism for predicting chemotherapeutic response
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
AU2001255226A1 (en) * 2000-03-31 2001-10-15 University Of Southern California Manganese superoxide dismutase gene polymorphism for predicting cancer susceptibility
US6518416B1 (en) * 2000-12-01 2003-02-11 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US7049059B2 (en) * 2000-12-01 2006-05-23 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
JPWO2003004640A1 (ja) * 2001-07-05 2004-10-28 大鵬薬品工業株式会社 抗癌剤感受性測定用ｄｎａアレイ
EP1436427B1 (en) * 2001-10-19 2008-08-06 Centre Hospitalier Régional et Universitaire de Tours Methods and compositions to evaluate antibody treatment response
EP2385137A1 (en) 2002-07-31 2011-11-09 University of Southern California Polymorphisms for predicting disease and treatment outcome
CA2503027A1 (en) * 2002-10-21 2004-05-06 University Of Medicine And Dentistry Of New Jersey Thymidylate synthase polymorphisms for use in screening for cancer susceptibility
EP1905847A3 (en) * 2003-01-10 2008-07-02 Pangaea Biotech, S.A. Assay device of XPD/ERCC2 gene polymorphisms for the correct administration of chemotherapy in lung cancer
US9109255B2 (en) * 2004-06-18 2015-08-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining responsiveness to antibody therapy
EP1774039A4 (en) * 2004-07-01 2009-07-08 Univ Southern California GENETIC MARKERS FOR PREDICTING THE DISEASE AND TREATMENT OUTPUT
WO2007064957A1 (en) 2005-11-30 2007-06-07 University Of Southern California FCγ POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME
EP1999278A4 (en) * 2006-03-03 2009-12-09 Univ Southern California GENETIC MARKERS FOR PREDICTING THE DISEASE AND TREATMENT OUTPUT
EP1991707A4 (en) * 2006-03-03 2012-11-21 Univ Southern California POLYMORPHISMS IN VOLTAGE-CONTROLLED SODIUM CHANNEL ALPHA-1 SUB-UNIT AS A MARKER FOR THERAPY SELECTION
WO2007103814A2 (en) * 2006-03-03 2007-09-13 University Of Southern California Angiogenesis pathway gene polymorphisms for therapy selection
WO2008088855A2 (en) 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms as predictors of tumor progression and their use in cancer therapy
EP2109686A2 (en) 2007-01-18 2009-10-21 University Of Southern California Genetic markers for predicting responsiveness to combination therapy
AU2008205471A1 (en) 2007-01-18 2008-07-24 University Of Southern California Tissue factor promoter polymorphisms
CA2675366A1 (en) 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual tki therapy
WO2008088860A2 (en) 2007-01-18 2008-07-24 University Of Southern California Polymorphisms in the egfr pathway as markers for cancer treatment
EP2126126A2 (en) 2007-01-18 2009-12-02 University Of Southern California Gene polymorphisms in vegf and vegf receptor 2 as markers for cancer therapy
CA2675370A1 (en) 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms as sex-specific predictors in cancer therapy
US9031642B2 (en) 2013-02-21 2015-05-12 Medtronic, Inc. Methods for simultaneous cardiac substrate mapping using spatial correlation maps between neighboring unipolar electrograms

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138388B2 (en) 2001-01-19 2006-11-21 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions
US7662553B2 (en) 2002-07-31 2010-02-16 University Of Southern California Polymorphisms in the ERCC1 gene for predicting treatment outcome
EP1654526A4 (en) * 2003-07-18 2009-12-02 Intelligenescan Inc SPECIAL GROUP OF BIOLOGICAL MARKERS FOR COLORECTAL CANCER
WO2005085473A3 (en) * 2004-03-01 2006-03-02 Univ Chicago Polymorphisms in the epidermal growth factor receptor gene promoter
WO2005098034A1 (en) * 2004-04-08 2005-10-20 Hiltrud Brauch Ercc2 polymorphisms
WO2006106316A3 (en) * 2005-04-04 2007-02-15 Dxs Ltd Polynucleotide primers
JP2008534025A (ja) * 2005-04-04 2008-08-28 ディー・エックス・エス・リミテッド ポリヌクレオチドプライマー
EP1866438B2 (en) † 2005-04-04 2015-12-23 QIAGEN Manchester Limited Polynucleotide primers
US9029084B2 (en) 2005-04-04 2015-05-12 Qiagen Manchester Limited Polynucleotide primers
WO2006106316A2 (en) 2005-04-04 2006-10-12 Dxs Limited Polynucleotide primers
EP2314717A1 (en) * 2005-04-04 2011-04-27 QIAGEN Manchester Limited Polynucleotide primers for the detection of mutations in EGFR
WO2007103823A3 (en) * 2006-03-03 2009-04-09 Univ Southern California Genetic markers for predicting disease and treatment outcome
EP1991268A4 (en) * 2006-03-03 2009-08-26 Univ Southern California ANGIOGENIC PATH GENEPOLYMORPHISMS FOR THERAPY SELECTION
US7807364B2 (en) 2006-03-03 2010-10-05 University Of Southern California Angiogenesis pathway gene polymorphisms for therapy selection
US7890267B2 (en) 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
WO2008021483A3 (en) * 2006-08-17 2009-03-26 Ordway Res Inst Prognostic and diagnostic method for disease therapy
WO2008088855A3 (en) * 2007-01-18 2008-12-11 Univ Southern California Gene polymorphisms as predictors of tumor progression and their use in cancer therapy
US8278061B2 (en) 2007-01-18 2012-10-02 University Of Southern California Polymorphisms in the EGFR pathway as markers for cancer treatment
US8435752B2 (en) 2007-01-18 2013-05-07 University Of Southern California Gene polymorphisms predictive for dual TKI therapy
WO2008089465A3 (en) * 2007-01-18 2009-04-23 Univ Southern California Gene polymorphisms as sex-specific predictors in cancer therapy
WO2009113989A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
US10342765B2 (en) 2009-02-06 2019-07-09 University Of Southern California Therapeutic compositions comprising monoterpenes
US8568968B2 (en) 2009-04-13 2013-10-29 University Of Southern California EGFR polymorphisms predict gender-related treatment
WO2010124239A3 (en) * 2009-04-24 2011-01-06 University Of Southern California Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancer

Also Published As

Publication number Publication date
EP1540012A4 (en) 2006-03-22
US20130196955A1 (en) 2013-08-01
WO2004011625A3 (en) 2004-11-11
AU2003257110A1 (en) 2004-02-16
EP2385137A1 (en) 2011-11-09
EP2385138A1 (en) 2011-11-09
EP2385139A1 (en) 2011-11-09
US20100173922A1 (en) 2010-07-08
CA2494262A1 (en) 2004-02-05
AU2003257110A8 (en) 2004-02-16
US20060094012A1 (en) 2006-05-04
EP1540012A2 (en) 2005-06-15
JP2005534686A (ja) 2005-11-17
US20120122946A1 (en) 2012-05-17
US7662553B2 (en) 2010-02-16

Similar Documents

Publication Publication Date Title
US7662553B2 (en) Polymorphisms in the ERCC1 gene for predicting treatment outcome
US8318426B2 (en) Polymorphisms in voltage-gated sodium channel alpha 1-subunit as markers for therapy selection
US20070218487A1 (en) Genetic markers for predicting disease and treatment outcome
US6716581B2 (en) Manganese superoxide dismutase gene polymorphism for predicting cancer susceptibility
US20120108441A1 (en) Polymorphisms in angiogenesis pathway genes associated with tumor recurrence in surgery treated cancer patients
US8216781B2 (en) Gene polymorphisms as predictors of tumor progression and their use in cancer therapy
US20100184773A1 (en) Germline Polymorphisms in the Angiogenic Pathway Predict Tumor Recurrence in Cancer Therapy
WO2013172918A1 (en) Ksr1 gene polymorphism for use in predicting outcome and therapy selection
US20110160216A1 (en) Thymidylate Synthase Haplotype is Associated with Tumor Recurrence in Stage II and Stage III Colon Cancer Patients
US8568968B2 (en) EGFR polymorphisms predict gender-related treatment
US20140005064A1 (en) Polymorphisms in angiogenesis pathway genes associated with tumor recurrence in surgery treated cancer patients
US20120288861A1 (en) Germline polymorphisms in the sparc gene associated with clinical outcome in gastric cancer
US20100286262A1 (en) Ptgs2 haplotypes
HK1171082A1 (en) Carcinoma diagnosis and treatments, based on odci genotype
HK1171082B (en) Carcinoma diagnosis and treatments, based on odci genotype
WO2011146406A1 (en) Germline polymorphisms in vegf predict clinical outcomes in cancer patients treated with sorafenib

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2494262

Country of ref document: CA

Ref document number: 2004524265

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003772163

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003772163

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006094012

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10522664

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10522664

Country of ref document: US